GENOTYPING OF HUMAN CYTOMEGALOVIRUS (HCMV) GLYCOPROTEIN B (GB
PATIENT'S OUTCOME Dieamant, D.C., Bonon, S.H.A., Murakami, M.M., Aranha, F.J.P., Duarte, G.O., Fernandes, V.C.A., de Souza, C., Costa, S.C.B., Vigorito, A.C. State University of Campinas, Campinas, Sao Paulo, Brazil
Based on sequence variation in the UL55 gene that encodes glycoprotein B (gB), human cytomegalovirus (HCMV) can be classified into four gB genotypes. There is little information about the CMV gB genotype and clinical outcome in patients who underwent an allogeneic hematopoietic stem cell transplant (HSCT) in Brazil. Objectives: The goal of this study was to determine the distribution of gB genotypes in allogeneic HSCT patients with CMV infection and the effect of gB type on clinical outcome including CMV disease. Study design: The diagnosis of HCMV infection after allogeneic HSCT was detected by Antigenemia (AGM) and Nested-PCR (N-PCR). All patients with CMV infection received ganciclovir preemptive treatment. Positive samples from patients with active HCMV infection were submitted to genotyping using the N-PCR to amplify a region of UL55, followed by restriction analysis based on HinfI and RsaI digestion and subsequent sequencing aligned with known CMV variants in GenBank. Results: Were evaluated 55 allogeneic HSCT recipients, 41/55 patients (74,5%) presented active HCMV infection detected by AGM and/or N-PCR, a median time of 32 days after the transplant. The distribution of HCMV gB genotypes in 30/41 patients with HCMV active infection was as follow: gB1, 14/30 (46,6%); gB2, 10/30 (33,3%); gB3, 2/30 (6,7%); gB4, 2/30 (6,7%) and two patients (6,7%) had mixed infection whit gB1+gB3 and gB2+gB3. The sequencing confirmed the four CMV gB genotypes. HCMV disease developed in 2 patients, characterized for gastrointestinal disease and these two patients had infection with a mixture of HCMV gB genotypes. Conclusions: in this study the most prevalent genotype in patients with HCMV active infection was gB type1 and moreover, the mixture of HCMV gB genotypes was associate with gastrointestinal disease. It suggests that gB genotypes may have influence on the patient's outcome in a Brazilian population.
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RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (SCT): RETRANSPLANTATION DOES NOT IMPROVE OUTCOME IN COMPARISON TO SUPPORTIVE CARE AND CHEMOTHERAPY Arnold, R., Hemmati, P., Terwey, T., Voung, L., le Coutre, P., Doerken, B., Massenkeil, G. Charit e University Medicine Berlin, Berlin, Germany
Relapse post allogeneic SCT is a life threatening event and we report here our treatment strategies.
Between 12/1994 and 6/2010 449 pts. (median age: 42 years, 16 -70) underwent allogeneic SCT from an unrelated (n 5 263) or a matched related (n 5 186) donor for treatment of acute myeloblastic leukemia, AML (n 5 277) or acute lymphocytic leukemia, ALL (n 5 172). 240 pts. were transplanted in CR1, 209 pts. beyond CR1. 241 pts. were male, 208 pts. were female. Post allogeneic SCT 193/449 pts. (43 %) are alive in complete remission (CR), 142/449 pts. (32 %) relapsed and 114/449 pts. (25 %) died due to non relapse mortality (NRM). In the 142 relapsed patients the median duration of remission post allogeneic SCT was short (5 months, 1 -135) and the median age of the patients at relapse was 43 years (17 -68). Our treatment strategies for relapse were as follows: Firstly stop of immunosuppression. Thereafter, in fit patients reinduction chemotherapy followed by 2 nd allogeneic SCT was given. Patients with contraindications received supportive care 6 chemotherapy or chemotherapy and DLI. 30/142 pts. underwent 2 nd allogeneic SCT for treatment of relapse (same donor n9, other donor n21) and 112/142 pts. received conventional therapy. Results: 2/30 pts. (7 %) are alive at 9 and 16 months after 2 nd allogeneic SCT and 28/30 pts. died at a median of 3 months (0 -15) post 2 nd SCT. Causes of death are leukemia in 21/28 pts. (75 %) at a median of 4 months (1 -13) post 2 nd SCT. 7/28 pts. (25 %) died due to NRM (gvhd, infection, toxicity) at a median of 1 month (0 -15) after 2 nd SCT. The time interval between relapse and 2 nd SCT was in median 4 months (1 -56). Survival after 1 st relapse in the Re-SCT group was 10 months (3 -69 months). With conventional therapy 7/112 pts. (6 %) are alive with a median follow-up of 17 months (2 -50) after relapse and 105/112 pts. are dead. Causes of death are leukemia in 104/105 pts., 2 nd malignancy in 1/105. Median survival after 1 st relapse and conventional therapy is 2 months (0.1 -50 months). In Conclusion: Prognosis of relapse after allogeneic SCT is dismal. The longer survival of the Re-SCT group in comparison to the conventional group might reflect a selection of better risk patients. Prospective studies are needed to identify patients who will benefit from a 2 nd SCT as compared to non-transplant treatment. Reduced-intensity conditioning (RIC) regimens that contain alemtuzumab are often associated with a high incidence of mixed chimerism and a low incidence of acute graft versus host disease (GVHD). Both observations may be due to alemtuzumab-mediated depletion of graft lymphocytes. To determine if the timing of alemtuzumab administration affects the incidences of mixed chimerism and acute GVHD, we compared the outcomes of 102 patients with non-malignant diseases who underwent RIC-HCT using fludarabine and melphalan at our institution with 2 different alemtuzumab schedules. Forty-nine patients received a proximal alemtuzumab schedule, consisting of a median dose of 1mg/kg alemtuzumab divided over 4-5 consecutive days between days -12 to -4. Fifty-two patients received a distal alemtuzumab schedule, consisting of a median dose of 2.6mg/kg alemtuzumab divided over 3-4 consecutive days between days -23 to -19. All patients engrafted at a median of 11.5 days with the exception of 1 patient in each group who died at days +7 and +15. Excluding these 2 patients, the overall incidence of acute rejection and/or mixed chimerism in the proximal group (2 patients with acute rejection) was 35/48 patients (73%) versus 20/51 patients (39%) in the distal group (no acute rejection) (p 5 0.01). Acute GVHD prophylaxis was rapidly weaned in the majority of patients with mixed chimerism. Six patients in the proximal group and 4 patients in the distal group received hematopoietic cell boost (p 5 0.16), and donor lymphocyte infusions (DLI) were administered to 18 patients in the proximal group and 5 patients in the distal group (p 5 0.002). Prior to these interventions, acute GVHD grades II-IV developed in only 1 patient in the proximal group (2%), and 9 patients in the distal group (17%) (p 5 0.05). Following these interventions, acute GVHD grades II-IV occurred in 7 patients in the proximal group and 6 patients in the distal group, making the total overall incidence of acute GVHD grades II-IV 16% in the proximal group versus 29% in the distal group (p 5 0.1). Ultimately, 4 patients in the proximal group and 1 patient in the distal group required a second transplant. We conclude that the timing of alemtuzumab significantly influences the incidences of both mixed chimerism and acute GVHD. Further studies to optimize the dosing schedule of alemtuzumab are warranted. Background: Work based on oral Busulfan (Bu) suggests low levels may be associated with rejection and high levels with toxicity. Data with IV Bu is sparse but generally in keeping with this. High Bu exposure (AUC . 6000mM.min) has been associated with worse outcome in adults given BuFlu or BuCy and in children after a variety Poster Session II S315 of regimens. Even with therapeutic drug monitoring of Bu, by the time results come back, patients may have had 1 or 2 days of high or low exposure. The required dose change to target a desired cumulative AUC may exceed the clinicians' willingness to make such a change. We report here our use of a novel dosing schedule which always avoids high exposure and is compatible with samples being sent across long distances for analysis. Methods: 96 patients from 6 institutions were given Bu over 5 days. Regimens included BuCy(n 5 36), BuFlu(n 5 24). Four blood samples were collected after infusion of a half dose on day 1 and transported to CHW. On day 2 the second half dose was given whilst Bu measurement and pharmacokinetic analysis was completed. A full dose AUC was predicted from the half dose results. On days 3 to 5 patients were administered the remaining Bu doses, modified where necessary based on the day 1 AUC. In 71 patients, repeat AUC analysis after a full dose allowed comparison of predicted with actual AUC. Results: The day 1 analysis predicted a full dose AUC range between 3148 and 12666mM.min. Thirty four patients would have had an AUC . 6000mM.min. For days 3 to 5, 34 had doses reduced and 10 had doses increased to target a desired AUC. After dose adjustments, the repeat AUC was within 610% predicted in 38 and within 615% in 51. Two of 36 adults had a final AUC value . 6000mM.min (but only 6097 and 6187). Conclusions: There was a wide variability in Bu exposure following the first dose: 35% of the patients were predicted to be exposed to levels above the recommended level of 6000mM.min. With dose adjustment, targeted dose exposure was within 615% of predicted values in 72% of patients and no adult was exposed to an AUC significantly . 6000mM.min. This novel dosing schedule allows realtime pharmacokinetic dose adjustment in multiple centres across Australia and avoids the problem of having to catch up, or back off on day 3 and 4 dosing. It is simple and lends itself to centres that are remote from the lab testing the Bu levels. The impact of concomitant medication on the remaining variability in exposure continues to be studied. Background: Tacrolimus (TAC) suppress T-cell activation by the action on calcineurin (CN). CN activity was assessed in the allogeneic recipients who were treated with TAC for graft-versus-host disease (GVHD) prophylaxis to investigate whether CN activity increased in patients with severe acute GVHD. Methods: Forty patients who underwent allogeneic stem cell transplantation (SCT) using TAC as GVHD prophylaxis were analyzed for GVHD. Among them, CN activity was analyzed in the 10 consecutive patients. TAC was administered at a dose of 0.03 mg/kg intravenously from day-1 to +21. TAC levels and CN activity were assessed on day-1 before TAC administration and days 0, +3, +7, +14, and +21. Target TAC concentration (15-20 ng/ml) was maintained during the current study. Results: The cumulative incidence of acute GVHD (74.1% vs. 60.3%, p 5 0.888) and severe chronic GVHD (22.5% vs. 33.3%, p 5 0.539) were not different between groups with high and low TAC trough levels. CN activity on day-1 was 0.1260.09 nmol and had decreased from baseline level (0.2960.15 nmol) (p \ 0.001). There was no correlation between CN activity and TAC concentrations (r 2 5 0.024). CN activity was steady-state during post-transplant day+0 to +14 regardless of acute GVHD, CN activity on day+21 for those with grade 2-4 acute GVHD showed a higher CN activity (0.1860.04 nmol) compared to those without grade 2-4 acute GVHD (0.1460.05 nmol, p 5 0.462). The cumulative incidence of acute GVHD (40% vs. 80%, p 5 0.248) and chronic GVHD (20% vs. 70%, p 5 0.464) between low and high CN activity group were not significantly different. Conclusion: Although GVHD was higher for the high CN activity group, this pilot study failed to demonstrate significant difference due to small sample size. However, the patients manifesting GVHD with high CN activity on post-transplant D+21 may need to be treated with other kinds of immunosuppressive agent regardless of drug level. Introduction: Acute graft-versus-host-disease (aGVHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT). The purpose of this study was to characterize the oral features associated with aGVHD. Methods: Patients that underwent allogeneic HCT at Dana-Farber/ Brigham and Women's Cancer Center (Boston, MA) between 1995 and 2010 and developed prominent oral aGVHD were identified. Data was collected from patient medical records using a standardized form and analyzed descriptively. Results: Eighteen cases were identified, of which 5 (28%) only demonstrated oral features; the remaining 13 had variable involvement of skin (13/18, 72%), liver (6/18, 33%), and gut (5/18, 28%). Oral mucositis preceded aGVHD in 10 (56%) patients. The median time to onset of oral aGVHD was 34 days (range 11-159). Intraoral sites affected by non-specific ulcerations included the tongue (16/18, 89%; dorsum in 7/18), buccal mucosa (16/18, 89%), labial mucosa (13/18, 72%), palate (12/18, 67%; hard palate in 7/18), and floor of mouth (6/18; 33%); 7 (39%) cases presented with prominent lip ulceration and crusting. Salivary gland disease features included severe hypofunction (1/18; 6%) and palatal mucoceles (1/18; 6%). In addition to systemic therapies, topical preparations of dexamethasone (10/ 18; 56%), tacrolimus (7/18; 39%), and morphine (3/18; 17%) were utilized for ancillary support. Of the 13 (72%) patients that survived beyond day100, two developed oral cGVHD. Conclusions: Oral features of aGVHD include extensive non-specific ulcerations of keratinized and non-keratinized mucosa and are often observed in the context of concurrent skin, liver and gut involvement. Intensive topical therapies may be helpful in reducing symptoms and promoting healing. Concurrent salivary gland involvement appears to be infrequent. Relevance: Oral medicine specialists can play an important role in both its diagnosis and management; the HCT team should be aware that aGVHD can present with oral features that might be responsive to topical therapies.
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SCREENING FOR HEMOGLOBINOPATHIES IN ALLOGENEIC CORD BLOOD UNITS USING CAPILLARY ELECTROPHORESIS Damianitsch, K., Platz, A., Schmidt, A., Ehninger, G. DKMS Cord Blood Bank, Blasewitzer Straße 43, Dresden, Germany Introduction: Hemoglobinopathies are common hereditary diseases with very different clinical outcomes. Since severe hemoglobinopathies like sickle cell anemia or thalassemia major are by themselves indications for transplantation, these inborn errors are relevant screening parameters for transplantation centers. In line with that, the international FACT-Netcord standards for the storage and release of cord blood units for transplantation (4 th edition) state that screening for homozygous hemoglobinopathies is mandatory for cord blood banks storing allogeneic transplants. Material and Methods: We use the Capillarys 2 hemoglobin electrophoresis machine and the Capillarys cord blood procedure by Sebia. Analyses are performed on anti-coagulated cord blood before volume reduction. The red blood cells are sedimented and plasma is removed completely. Before measuring the samples are hemolysed automatically. Results: So far, a total of 717 measurements were performed. In 1.5% of all samples hemoglobin variants were detected, namely six cases of Hb Barts, three cases of heterozygous Hb S and one case of a heterozygous hemoglobin variant, most likely Hb E. These samples were then sent to a specialized laboratory for PCR-testing, and
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